In this task, you are given text for US Congressional and California state bills, your task is to generate a summary for this bill.

[EX Q]: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Adult Day Center Enhancement Act''.

SEC. 2. FINDINGS.

The Congress finds the following:
(1) One in 6 people in the United States lives with a
neurological disease or condition that can often result in
disability, and which may require the individual to seek
assistance in carrying out the activities of daily living.
Neurological diseases or conditions such as multiple sclerosis
(MS), early-onset Parkinson's disease, and traumatic brain
injury (TBI) can also typically affect younger adults in the
middle of their lives.
(2) Multiple sclerosis is a chronic, often disabling
disease that attacks the central nervous system with symptoms
ranging from numbness in limbs to paralysis and loss of vision.
Most people with MS are diagnosed between the ages of 20 and 50
years of age. MS is a leading cause of disability in young
adults. Persons living with MS who experience more severe forms
of the disease are likely to require either home care or
nursing home placement, though the vast majority would prefer
to remain at home to receive the care they need. Where home
care is concerned, approximately 80 percent of such care is
provided by unpaid caregivers who are generally family members.
(3) Parkinson's disease is a chronic, progressive
neurological disease. The four primary symptoms of Parkinson's
disease are tremor, or trembling in hands, arms, legs, jaw, and
face; rigidity, or stiffness of the limbs and trunk;
bradykinesia, or slowness of movement; and postural
instability, or impaired balance and coordination. Other
symptoms may include cognitive changes; difficulty in
swallowing, chewing, and speaking; urinary problems or
constipation; skin problems; and sleep disruptions. As these
symptoms become more pronounced, patients may have difficulty
walking, talking, or completing other simple tasks. It is
estimated that nearly 500,000 to 1,500,000 people live with
Parkinson's and of those 5 to 10 percent are diagnosed younger
than 60 and deemed ''early-onset''.
(4) Traumatic brain injury is a neurological condition that
typically results from a blow or jolt to the head or a
penetrating head injury and that can impact one or more parts
of the brain, thereby temporarily or permanently disrupting
normal brain function. The Centers for Disease Control and
Prevention estimates that 1,700,000 TBIs occur annually,
resulting in disabilities affecting up to 90,000 people among a
broad range of age groups. Traumatic brain injury is also a
serious issue that affects military servicemembers. Estimates
in prior military conflicts indicate that TBI was present in
14-20 percent of surviving casualties.
(5) Family caregivers are a crucial source of support and
assistance for individuals suffering with disabilities. Family
caregivers, the majority of whom are women, provide an
estimated $470,000,000,000 in ''free'' services annually. The
supply of family caregivers is unlikely to keep pace with
future demand. The caregiver support ratio of potential
caregivers aged 45 to 64 for each person aged 80 and older, for
instance, is 7 to 1 in 2010, 4 to 1 in 2030, and 3 to 1 in
2050.
(6) The majority of family caregivers (or 53 percent) are
caring for someone ages 18 to 74. Forty-seven percent of family
caregivers are caring for someone 75 or older.
(7) Adult day programs can offer services, including
medical care, rehabilitation therapies, dignified assistance
with the activities of daily living, nutrition therapy, health
monitoring, social interaction, stimulating activities, and
transportation to seniors, people with disabilities, and
younger adults with chronic diseases.
(8) Adult day programs geared toward people living with
neurological diseases or conditions such as MS, Parkinson's
disease, TBI, or other similar diseases or conditions provide
an important response to the needs of people living with these
conditions and their family caregivers. Adult day programs can
help to ameliorate symptoms, reduce dependency, provide
important socialization opportunities, and maintain quality of
life.
(9) Adult day programs have been shown to provide a range
of documented benefits including improvements in functional
status, social support, and reductions in fatigue, depression
and pain. Adult day programs also reduce ongoing medical care
and hospital costs and decrease admissions to nursing home
facilities, which can be costly for many families, by allowing
individuals to receive health and social services while
continuing to live at home.
(10) There are currently few adult day programs focused on
younger adult populations in the United States. Although young
people living with neurological diseases or conditions may be
able to access existing adult day programs, such programs are
not typically intended for younger adults living with chronic
diseases or conditions, and may not provide the appropriate
services to meet the age-related or disability status of these
individuals.

SEC. 3. ESTABLISHMENT OF ADULT DAY PROGRAMS.

(a) Survey of Existing Adult Day Programs.--
(1) In general.--Not later than 90 days after the date of
the enactment of this section, the Assistant Secretary for
Aging shall initiate a comprehensive survey of current adult
day programs that provide care and support to individuals
including young adults living with neurological diseases or
conditions such as multiple sclerosis, Parkinson's disease,
traumatic brain injury, or any similar disease or condition.
(2) Survey elements.--In carrying out the survey under
paragraph (1), the Assistant Secretary for Aging may utilize
existing publicly available research on adult day programs, and
shall--
(A) identify ongoing successful adult day programs,
including by providing a brief description of how such
programs were initially established and funded;
(B) identify which adult day programs are serving
young adults living with neurological diseases or
conditions;
(C) develop a set of best practices to help guide
the establishment and replication of additional
successful adult day programs, including--
(i) program guidelines;
(ii) recommendations on the scope of
services that should be provided to individuals
with neurological diseases or conditions
including young adults (which may include
rehabilitation therapy, psychosocial support,
social stimulation and interaction, and
spiritual, educational, or other such
services); and
(iii) performance goals and indicators to
measure and analyze the outcomes generated by
the services provided and to evaluate the
overall success of the program; and
(D) evaluate the extent to which the Administration
for Community Living supports adult day programs,
either directly or indirectly, through current Federal
grant programs.
(3) Report.--Not later than 180 days after initiating the
survey under paragraph (1), the Assistant Secretary for Aging
shall produce and make publicly available a summary report on
the results of the survey. Such report shall include each of
the elements described in paragraph (2).
(b) Establishment of Grant Program.--
(1) In general.--Not later than 90 days after producing the
report required by subsection (a)(3), the Assistant Secretary
for Aging shall establish within the Administration for
Community Living a competitive grant program for awarding
grants annually to eligible entities, based on the best
practices developed under subsection (a), to fund adult day
programs serving younger people with neurological diseases or
conditions.
(2) Eligible entities.--In order to be eligible for a grant
under this subsection, an entity shall demonstrate the
following:
(A) Understanding of the special needs of younger
people living with neurological diseases or conditions
such as multiple sclerosis, Parkinson's disease,
traumatic brain injury, or other similar diseases or
conditions, including their functional abilities and
the potential complications across all types of cases
and stages of such diseases or conditions.
(B) Understanding of the issues experienced by
family caregivers who assist a family member with
neurological diseases or conditions such as multiple
sclerosis, Parkinson's disease, traumatic brain injury,
or other similar diseases or conditions.
(C) A capacity to provide the services recommended
by the best practices developed under subsection (a).
(3) Additional selection requirement.--The Assistant
Secretary for Aging shall not award a grant to an entity under
this subsection if the amount of the award would constitute
more than 40 percent of the operating budget of the entity in
the fiscal year for which funds for the grant are authorized to
be expended. For purposes of this subsection, the fair market
value of annual in-kind contributions of equipment or services
shall be considered as part of the operating budget of the
entity.
(4) Selection of grant recipients.--Not later than 90 days
after establishing the grant program under this subsection, the
Assistant Secretary for Aging shall award the first annual
series of grants under the program. In awarding grants under
this subsection, the Assistant Secretary should ensure, to the
extent practicable, a diverse geographic representation among
grant recipients and that, subject to the availability of
appropriations--
(A) a minimum of 5 entities are selected as grant
recipients for the first fiscal year for which such
grants are awarded;
(B) a minimum of 10 entities are selected as grant
recipients for the second such fiscal year;
(C) a minimum of 12 entities are selected as grant
recipients for the third such fiscal year; and
(D) a minimum of 15 entities are selected as grant
recipients for the fourth such fiscal year.
(5) Report.--No later than 1 year after the initial award
of grants under this subsection, and annually thereafter, the
Assistant Secretary for Aging shall produce and make publicly
available a brief summary report on the grant program under
this section. Each such report shall include the following:
(A) A description of the adult day programs
receiving funding under this section, including the
amount of Federal funding awarded and the expected
outcomes of each program.
(B) A description of performance goals and
indicators to monitor the progress of grant recipients
in--
(i) responding to the needs of younger
individuals living with neurological diseases
or conditions such as multiple sclerosis,
Parkinson's disease, traumatic brain injury, or
other similar diseases or conditions; and
(ii) assisting the family caregivers of
such individuals.
(C) Any plans for improving oversight and
management of the grant program.
(c) Definitions.--In this Act:
(1) The term ''adult day program'' means a program that
provides comprehensive and effective care and support services
to individuals living with neurological diseases or conditions
such as multiple sclerosis, Parkinson's disease, traumatic
brain injury, or other similar diseases or conditions that may
result in a functional or degenerative disability and to their
family caregivers and that may assist participants in ways
that--
(A) maintain or improve their functional abilities,
or otherwise help them adjust to their changing
functional abilities;
(B) prevent the onset of complications associated
with severe forms of the disease or condition;
(C) promote alternatives to placement in nursing
homes;
(D) reduce the strain on family caregivers taking
care of a family member living with such diseases or
conditions;
(E) focus on supporting the emotional, social, and
intellectual needs of a younger adult population; or
(F) address the needs of veterans living with such
diseases or conditions.
(2) The term ''family caregiver'' means a family member or
foster parent who provides unpaid assistance (which may include
in-home monitoring, management, supervision, care and
treatment, or other similar assistance) to another adult family
member with a special need.
(d) Authorization of Appropriations.--To carry out this section, in
addition to amounts otherwise made available for such purpose, there
are authorized to be appropriated, and to remain available until
expended, the following:
(1) $1,000,000 for fiscal year 2017.
(2) $3,000,000 for fiscal year 2018.
(3) $6,000,000 for fiscal year 2019.
(4) $8,000,000 for fiscal year 2020.
(5) $10,000,000 for fiscal year 2021.
[EX A]: Adult Day Center Enhancement Act This bill requires the Administration on Aging (AOA) to initiate a comprehensive survey of current adult day programs that provide care and support to individuals with neurological diseases or conditions such as multiple sclerosis, Parkinson's disease, or traumatic brain injury. The AOA must identify ongoing successful adult day programs and which of these serve young adults with neurological conditions and develop best practices to guide the establishment of additional successful adult day programs. The AOA must award grants for adult day programs that serve younger people with neurological conditions. An "adult day program" is defined as a program that provides comprehensive care and support services to individuals with neurological conditions and to their family caregivers and that may assist participants in ways that: maintain or improve their functional abilities or otherwise help them adjust to their changing functional abilities; prevent the onset of complications associated with severe forms of the condition; promote alternatives to placement in nursing homes; reduce the strain on family caregivers of individuals with neurological conditions; focus on supporting the emotional, social, and intellectual needs of a younger adult population; or address the needs of veterans with neurological conditions.

[EX Q]: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Expanding Access to Medical Records
Act''.

SEC. 2. FULL ACCESS TO MEDICARE INFORMATION BY THE AUTHORIZED
REPRESENTATIVE OF A DECEASED BENEFICIARY.

(a) In General.--Title XVIII of the Social Security Act (42 U.S.C.
1395 et seq.) is amended by adding at the end the following new
section:

''full access to medicare information by the authorized representative
of a deceased beneficiary

''Sec. 1899. (a) In General.--In the case of the death of an
individual entitled to, or enrolled for, benefits under part A or
enrolled for benefits under part B, the Secretary shall--
''(1) make available to the authorized representative of
the individual all information concerning the individual's
benefits under this title, including--
''(A) the coverage and status of such benefits (as
of the day before the individual's death); and
''(B) billing, claims, and payment information
regarding items and services furnished to the
individual under this title (on or before such day);
and
''(2) provide such authorized representative access to any
source of information maintained by the Federal government with
respect to such benefits, including online databases, that the
individual had access to during his or her lifetime.
''(b) Definition of Authorized Representative; Special Rules.--
''(1) In general.--In this section, the term 'authorized
representative' means an executor, administrator, or other
individual who has authority to act on the deceased
individual's behalf (as determined by the Secretary under
paragraph (2)).
''(2) Determination of authorized representative.--
''(A) In general.--The Secretary shall establish
procedures under which the Secretary determines whether
an individual is an authorized representative of the
deceased individual. Under such procedures, the
individual seeking such determination shall provide
evidence (in such form and such manner as specified by
the Secretary) of the individual's legal authority to
act on behalf of the deceased individual.
''(B) Timeline for determination.--The Secretary
shall make a determination under subparagraph (A) not
later than 30 days after receipt of the evidence
described in such subparagraph.
''(3) Notification and access to information.--After making
a determination under paragraph (2) with respect to an
individual, the Secretary shall--
''(A) notify the individual of the determination
not later than 7 days after the date on which the
determination is made; and
''(B) in the case where such individual is so
determined to be the authorized representative of the
deceased individual, as soon as practicable--
''(i) make available to the authorized
representative the information described in
paragraph (1) of subsection (a); and
''(ii) provide the authorized
representative access to the sources described
in paragraph (2) of such subsection.''.
(b) Effective Date.--The amendment made by this section shall take
effect on the date that is 60 days after the date of enactment of this
Act.

SEC. 3. FULL ACCESS TO MEDICAID INFORMATION BY THE AUTHORIZED
REPRESENTATIVE OF A DECEASED BENEFICIARY.

(a) In General.--Title XIX of the Social Security Act (42 U.S.C.
1396 et seq.) is amended by adding at the end the following new
section:

''full access to medicaid information by the authorized representative
of a deceased beneficiary

''Sec. 1943. (a) In General.--In the case of the death of an
individual enrolled under the State plan for medical assistance or
under a waiver of such plan, the State Medicaid agency shall--
''(1) make available to the authorized representative of
the individual all information concerning the individual's
benefits under this title, including--
''(A) the coverage and status of such benefits (as
of the day before the individual's death); and
''(B) billing, claims, and payment information
regarding items and services furnished to the
individual under this title (on or before such day);
and
''(2) provide such authorized representative access to any
source of information maintained by the State with respect to
such benefits, including online databases, that the individual
had access to during his or her lifetime.
''(b) Definition of Authorized Representative; Special Rules.--
''(1) In this section, the term 'authorized representative'
means an executor, administrator, or other individual who has
authority to act on the deceased individual's behalf (as
determined by the State Medicaid agency under paragraph (2)).
''(2) Determination of authorized representative.--
''(A) In general.--The State Medicaid agency shall
establish procedures under which such agency determines
whether an individual qualifies as an authorized
representative of the deceased individual. Under such
procedures, the individual seeking such a determination
shall provide evidence (in such form and such manner as
specified by the State Medicaid Agency) of the
individual's legal authority to act on behalf of the
deceased individual.
''(B) Timeline for determination.--The State
Medicaid agency shall make a determination under
subparagraph (A) not later than 30 days after receipt
of the evidence described in such subparagraph.
''(3) Notification and access to information.--After making
a determination under paragraph (2) with respect to an
individual, the State Medicaid Agency shall--
''(A) notify the individual of the determination
not later than 7 days after the date on which the
determination is made; and
''(B) in the case where such individual is so
determined to be the authorized representative of the
deceased individual, as soon as practicable--
''(i) make available to the authorized
representative the information described in
paragraph (1) of subsection (a); and
''(ii) provide the authorized
representative access to the sources described
in paragraph (2) of such subsection.
''(c) Definition of State Medicaid Agency.--The term 'State
Medicaid agency' means the State agency responsible for administering
the State plan established under this title or any waiver of such
plan.''.
(b) Effective Date.--
(1) In general.--Except as provided in paragraph (2), the
amendment made by this section shall take effect on the date
that is 60 days after the date of enactment of this Act.
(2) Extension of effective date for state law amendment.--
In the case of a State plan under this title which the
Secretary of Health and Human Services determines requires
State legislation in order for the plan to meet the additional
requirements imposed by the amendment made by subsection (a),
the State plan shall not be regarded as failing to comply with
the requirements of such title solely on the basis of its
failure to meet these additional requirements before the first
day of the first calendar quarter beginning after the close of
the first regular session of the State legislature that begins
after the date of the enactment of this Act. For purposes of
the previous sentence, in the case of a State that has a 2-year
legislative session, each year of the session is considered to
be a separate regular session of the State legislature.
[EX A]: Expanding Access to Medical Records Act - Amends titles XVIII (Medicare) and XIX (Medicaid) of the Social Security Act to require the Secretary of Health and Human Services (HHS) grant the authorized representative of a deceased beneficiary full access to information with respect to the deceased beneficiary's benefits under the Medicare and Medicaid programs.

[EX Q]: SECTION 1. SHORT TITLE.

This Act may be cited as the ''Dextromethorphan Abuse Reduction Act
of 2007''.

SEC. 2. FINDINGS.

Congress finds the following:
(1) When used properly, cough medicines that contain
dextromethorphan have a long history of being safe and
effective. But abuse of dextromethorphan at high doses can
produce hallucinations, rapid heart beat, high blood pressure,
loss of consciousness, and seizures. The dangers multiply when
dextromethorphan is abused with alcohol, prescription drugs, or
narcotics.
(2) Dextromethorphan is inexpensive, legal, and readily
accessible, which has contributed to the increased abuse of
that drug, particularly among teenagers.
(3) Increasing numbers of teens and others are abusing
dextromethorphan by ingesting it in excessive quantities.
Prolonged use at high doses can lead to psychological
dependence on the drug. Abuse of dextromethorphan can also
cause impaired judgment, which can lead to injury or death.
(4) Dextromethorphan abuse increased by a factor of 10
during the period of 1999 through 2004, with an increase by a
factor of 15 among children aged 9 to 17 years.
(5) An estimated 2,400,000 teenagers (1 in 10) abused over-
the-counter cough medicines in 2005. Children ages 9 to 17
years are the fastest growing group of dextromethorphan
abusers.
(6) The Food and Drug Administration has called the abuse
of dextromethorphan a ''serious issue'' and a ''disturbing new
trend'' that can cause ''death as well as other serious adverse
events such as brain damage, seizure, loss of consciousness,
and irregular heartbeat.''.
(7) In recognition of the problem, several retailers have
voluntarily implemented age restrictions on purchases of cough
and cold medicines containing dextromethorphan.
(8) Prevention is a key component of addressing the rise in
the abuse of legal medications. Education campaigns teaching
teens and parents about the dangers of these drugs are an
important part of this effort.

SEC. 3. DEXTROMETHORPHAN.

(a) Definitions.--Section 102 of the Controlled Substances Act (21
U.S.C. 802) is amended by adding at the end the following:
''(50) The term 'finished dosage form', relating to
dextromethorphan, means dextromethorphan that--
''(A) is--
''(i) in a tablet, capsule, solution, liquid, or
other form intended for retail sale, and that generally
contains inactive ingredients; and
''(ii) approved under the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 301 et seq.) as a
nonprescription drug (as that term is defined in
section 760 of that Act (21 U.S.C. 379aa)); or
''(B) has been combined with other active or inactive
ingredients during the process of manufacturing a tablet,
capsule, solution, liquid, or other form described in
subparagraph (A).
''(51) The term 'unfinished', relating to dextromethorphan, means
any concentration or amount of dextromethorphan that is not in finished
dosage form.''.
(b) Unfinished Dextromethorphan.--Schedule V of section 202(c) of
the Controlled Substances Act (21 U.S.C. 812(c)) is amended by adding
at the end the following:
''(6) Unfinished dextromethorphan.''.
(c) Sales of Dextromethorphan in Finished Dosage Form.--
(1) In general.--Part D of title II of the Controlled
Substances Act (21 U.S.C. 841 et seq.) is amended by adding at
the end the following:

''SEC. 424. CIVIL PENALTIES FOR CERTAIN DEXTROMETHORPHAN SALES.

''(a) In General.--
''(1) Sale.--
''(A) In general.--Except as provided in paragraph
(2), it shall be unlawful for any person to knowingly
sell, cause another to sell, or conspire to sell a
product containing dextromethorphan to an individual
under the age of 18 years, including any such sale
using the Internet.
''(B) Failure to check identification.--If a person
fails to request identification from an individual
under the age of 18 years and sells a product
containing dextromethorphan to that individual, that
person shall be deemed to have known that the
individual was under the age of 18 years.
''(C) Affirmative defense.--It shall be an
affirmative defense to an alleged violation of
subparagraph (A) that the person selling a product
containing dextromethorphan examined the purchaser's
identification card and, based on that examination,
that person reasonably concluded that the
identification was valid and indicated that the
purchaser was not less than 18 years of age.
''(2) Exception.--This section shall not apply to any sale
made pursuant to a validly issued prescription.
''(b) Fines.--
''(1) In general.--The Attorney General may impose a civil
penalty on a person for violating subsection (a)(1)(A),
including a violation of that subsection committed by an
employee or agent of such person.
''(2) Maximum amount.--A civil penalty imposed under
paragraph (1) shall be--
''(A) not more than $1,000 for the first violation
of subsection (a)(1)(A) by a person;
''(B) not more than $2,000 for the second violation
of subsection (a)(1)(A) by a person; and
''(C) not more than $5,000 for the third violation,
or a subsequent violation, of subsection (a)(1)(A) by a
person.
''(3) Number of violations.--If a person makes sales of
dextromethorphan at more than 1 location, for purposes of
determining the number of violations by that person under this
subsection each individual location operated by that person
shall be considered a separate person.
''(c) Definition of Identification Card.--In this section, the term
'identification card' means an identification card that--
''(1) includes a photograph and the date of birth of the
individual;
''(2) is issued by a State or the Federal Government; and
''(3) is considered acceptable for purposes of sections
274a.2(b)(1)(v)(A) and 274a.2(b)(1)(v)(B)(1) of title 8, Code
of Federal Regulations (as in effect on or after the date of
the enactment of the Dextromethorphan Abuse Reduction Act of
2007).''.
(2) Regulations.--
(A) Internet sales.--Not later than 180 days after
the date of enactment of this Act, the Attorney General
of the United States shall promulgate regulations for
Internet sales of products containing dextromethorphan
to ensure compliance with section 424 of the Controlled
Substances Act, as added by this Act.
(B) Civil penalties.--
(i) In general.--Not later than 180 days
after the date of enactment of this Act, the
Attorney General of the United States shall
promulgate regulations to carry out section 424
of the Controlled Substances Act, as added by
this Act.
(ii) Contents.--The regulations promulgated
under clause (i) shall--
(I) provide for a range of fines
for a retailer, based on whether the
retailer or an employee or agent of
that retailer has committed prior
violations of section 424(a) of the
Controlled Substances Act, as added by
this Act; and
(II) require consideration of
whether a fine to be imposed on a
retailer should be reduced or
eliminated based on--
(aa) the establishment and
administration of an effective
employee training program by a
retailer relating to this Act
and the amendments made by this
Act; or
(bb) other actions taken by
a retailer to ensure compliance
with this Act and the
amendments made by this Act.
(C) Definition of retailer.--In this paragraph, the
term ''retailer'' means a grocery store, general
merchandise store, drug store, convenience store, or
other entity or person whose activities as a
distributor relating to products containing
dextromethorphan are limited almost exclusively to
sales for personal use, both in number of sales and
volume of sales, either directly to walk-in customers
or in face-to-face transactions by direct sales.
(3) Sense of the senate.--It is the sense of the Senate
that--
(A) manufacturers of products containing
dextromethorphan should contain language on packages
cautioning consumers about the dangers of
dextromethorphan misuse; and
(B) retailers selling products containing
dextromethorphan should impose appropriate safeguards
to protect against the theft of such products.
(d) Prevention Funding.--
(1) The partnership for a drug-free america.--
(A) In general.--The Director of National Drug
Control Policy shall make a directed grant to the
Partnership for a Drug-Free America to provide
education to individuals under the age of 18 years and
parents regarding preventing the abuse of prescription
and nonprescription drugs (including dextromethorphan).
(B) Authorization of appropriations.--In addition
to any other amounts authorized to be appropriated,
there are authorized to be appropriated $4,000,000 for
each of fiscal years 2008 through 2010 to carry out
this paragraph.
(2) Community anti-drug coalition of america.--
(A) In general.--The Director of National Drug
Control Policy shall make a directed grant to the
Community Anti-Drug Coalition of America to provide
education, training, and technical assistance to
community coalitions regarding preventing the abuse of
prescription and nonprescription drugs (including
dextromethorphan).
(B) Authorization of appropriations.--There are
authorized to be appropriated $4,000,000 for each of
fiscal years 2008 through 2010 to carry out this
paragraph.
(3) Supplement not supplant.--Grant funds provided under
this subsection shall be used to supplement, not supplant,
Federal and non-Federal funds available for carrying out the
activities described in this subsection.
(e) Supplemental Grants for Communities With Major Prescription and
Nonprescription Drug Issues.--
(1) Definitions.--In this subsection--
(A) the term ''Administrator'' means the
Administrator of the Substance Abuse and Mental Health
Services Administration;
(B) the term ''drug'' has the meaning given that
term in section 201 of the Federal Food, Drug, and
Cosmetic Act (21 U.S.C. 321);
(C) the term ''eligible entity'' means an
organization that--
(i) on or before the date of submitting an
application for a grant under this subsection,
receives a grant under the Drug-Free
Communities Act of 1997 (21 U.S.C. 1521 et
seq.); and
(ii) has documented, using local data,
rates of prescription or nonprescription drug
abuse above national averages, as determined by
the Administrator (including appropriate
consideration of the Monitoring the Future
Survey by the University of Michigan), for
comparable time periods;
(D) the term ''nonprescription drug'' has the
meaning given that term in section 760 of the Federal
Food, Drug, and Cosmetic Act (21 U.S.C. 379aa); and
(E) the term ''prescription drug'' means a drug
described in section 503(b)(1) of the Federal Food,
Drug, and Cosmetic Act (21 U.S.C. 353(b)(1)).
(2) Authorization of program.--The Administrator, in
consultation with the Director of the Office of National Drug
Control Policy, may make enhancement grants to eligible
entities to implement comprehensive community-wide strategies
that address abuse of prescription and nonprescription drugs.
(3) Application.--
(A) In general.--An eligible entity desiring an
enhancement grant under this subsection shall submit an
application to the Administrator at such time, in such
manner, and accompanied by such information as the
Administrator may require.
(B) Criteria.--As part of an application for a
grant under this subsection, the Administrator shall
require an eligible entity to submit a detailed,
comprehensive, multisector plan for addressing abuse of
prescription and nonprescription drugs.
(4) Uses of funds.--An eligible entity that receives a
grant under this subsection shall use the grant funds for
implementing a comprehensive, community-wide strategy that
addresses abuse of prescription and nonprescription drugs
issues in that community, in accordance with the plan submitted
under paragraph (3)(B).
(5) Grant terms.--A grant under this subsection--
(A) shall be made for a period of not more than 4
years; and
(B) shall not be in an amount of more than $50,000
per year.
(6) Supplement not supplant.--Grant funds provided under
this subsection shall be used to supplement, not supplant,
Federal and non-Federal funds available for carrying out the
activities described in this subsection.
(7) Evaluation.--A grant under this subsection shall be
subject to the same evaluation requirements and procedures as
the evaluation requirements and procedures imposed on the
recipient of a grant under the Drug-Free Communities Act of
1997 (21 U.S.C. 1521 et seq.).
(8) Administrative expenses.--Not more than 6 percent of a
grant under this subsection may be expended for administrative
expenses.
(9) Authorization of appropriations.--There are authorized
to be appropriated $4,000,000 for each of fiscal years 2008
through 2010 to carry out this subsection.
(f) Data Collection.--It is the Sense of the Senate that Federal
agencies and grantees that collect data on drug use trends should
ensure that the survey instruments used by such agencies and grantees
include questions to ascertain changes in the trend of abuse of
prescription and nonprescription drugs.
(g) Technical and Conforming Amendments.--
(1) In general.--Section 201(g) of the Controlled
Substances Act (21 U.S.C. 811(g)) is amended--
(A) by striking paragraph (2); and
(B) by redesignating paragraph (3) as paragraph
(2).
(2) Table of contents.--The table of contents for the
Comprehensive Drug Abuse Prevention and Control Act of 1970
(Public Law 91-513; 84 Stat. 1236) is amended by inserting
after the item relating to section 423 the following:

''Sec. 424. Dextromethorphan sales.''.
[EX A]:
Dextromethorphan Abuse Reduction Act of 2007 - Amends the Controlled Substances Act to: (1) set forth definitions relating to dextromethorphan in unfinished or finished dosage form; (2) classify unfinished dextromethorphan as a Schedule V controlled substance; and (3) impose civil penalties for sales of products containing dextromethorphan to individuals under the age of 18.

Expresses the sense of the Senate that: (1) manufacturers of products containing dextromethorphan should provide warnings about the dangers of dextromethorphan misuse; and (2) retailers should impose safeguards to protect against the theft of products containing dextromethorphan.

Directs the Director of National Drug Control Policy to make grants to the Partnership for a Drug-Free America and the Community Anti-Drug Coalition of America for education programs to prevent the abuse of prescription and nonprescription drugs (including dextromethorphan).

Authorizes the Administrator of the Substance Abuse and Mental Health Services Administration to make grants to certain communities to implement comprehensive community-wide strategies for addressing abuse of prescription and nonprescription drugs.